Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients
Active, not recruiting · NCT03679650 · Registry updated 2026-09-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 | 2026-09-29 | NCT03679650 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beth Israel Deaconess Medical Center | 161 |
| Dana-Farber Cancer Institute | 324 |
| National Cancer Institute (NCI) | 3015 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Dana Farber Cancer Institute | Boston | United States | 300 |